Liquid Biopsy Assays For ctDNA Detection Infographic

Liquid Biopsy Assays For ctDNA Detection

In recent years, liquid biopsies have rapidly evolved and have had a dramatic impact on the field of clinical oncology. Most importantly, their non-invasive nature enables clinicians to isolate, continuously monitor and analyze genetic material circulating around the body including circulating tumor DNA (ctDNA), without any additional complications for the patient. For translational scientists, assays which enable sensitive and accurate detection of patient ctDNA can accelerate the progression of targeted therapies into the clinic and ensure the best treatment decisions are made for patients.

Liquid Biopsy Assays For ctDNA Detection Infographic

This detailed and complimentary infographic outlines a case study of how developers can select an appropriate Liquid Biopsy Assay for ctDNA Detection using Beacon Biomarkers & Assays.

Download Infographic

You May Also Be Interested In…

ASCO 2026 Highlights: Where Oncology is Moving Next

View Infographic

T-Cell Engager Patents: Commercial Activity and Innovation Insights

View Infographic

The 2026 RAS Drug Development Landscape

View Market Report

View All

What is Beacon?

Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.

Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.

This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.

We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!

Request Demonstration